Sicknesses caused by colonic transit dysfunction are commonly seen in clinical practice.The transit dysfunction of the colon has been studied in recent decades on the primary abnormalitie,the secondary damage of the colon enteric nervous system,the distribution of Cajal interstitial cells with the c-kit protein expression of its surface,the damage of smooth muscle by autoimmune,the absorption of water by colon,viral infections and the genetic aspects.

Objective To explore the expression of insulin-like growth factors and their receptor (IGF- I R) in a human colorectal cancer cell line HT-29, and the effect of two IGF- I R monoclonal antibodies on the biological behavior of HT-29 cell lines. Methods Immunohistochemistry was used to test the expression of IGF- I R in HT-29 cell lines. MTT assay was used to determine the anti-proliferation effects of IGF- I R monoclonal antibody (McAb). Apoptosis percentage was estimated by flow cytometry ( FCM). Results IGF- I R was expressed in the membranes of HT-29 cell lines. McAb of IGH- I R can inhibit the proliferation of HT-29 cell lines in a dose-dependent manner. The apoptosis rate of HT-29 cells treated by IGF- I R McAb was higher than that of control group (P

OBJECTIVE:To systematically review the efficacy of folic acid in the prevention of gastrointestinal(GI)tumors in elder,and provide evidence-based reference for the clinical treatment. METHODS:Retrieved from Cochrane Library,PubMed,EM-Base,Web of Science,CMB,CJFD,VIP and Wanfang Database,the randomized controlled trials (RCT) about folic acid (test group)versus placebo(control group)in the prevention of GI tumors in elder(age>50 years old). After quality evaluation and da-ta extract,Meta-analysis was performed buy using Rev Man 5.3 statistics software. RESULTS:A total of 9 RCT were included,in-volving 29 494 patients. Results of Meta-analysis showed there was no significant difference in the incidence of GI tumors between 2 groups[RR=0.91,95%CI(0.74,1.12),P=0.38]. Results of subgroup analysis showed the incidence of GI tumors was not affected by GI tumor stage,age,basic serum folic acid level,type and dose of folic acid and follow-up time during follow-up period. CON-CLUSIONS:Folic acid supplement can not effectively prevent the incidence of GI tumors in elder. The incidence of GI tumors in elder with different ages and baseline of folic acid are not decreased by any dose and duration,without obvious adverse reactions. It indicates that folic acid supplement should be careful and give full conscideration to the patients’general situation. Due to the limit of methodological quality and sample size,it remains to be further verified with more rigorously designed and long-term follow-up of large-scale RCT.

Objective To study the perioperative predictors of portal vein thrombosis (PVT) after splenectomy in cirrhotic patients.Methods We searched the Web of Science,PubMed,EMBASE,Science Direct,CNKI,VIP,CSCD,and Wan Fang Databases up to April 2014.Only case-controlled studies which evaluated predictive factors of portal vein thrombosis (PVT) after splenectomy in cirrhotic patients were included.The Stata 12 software was used to perform the meta-analysis.Results Twenty-four casecontrolled studies were included.The sample size was 4 335,and the incidence rate of PVT was 25.0％.The risk factors of PVT included splenic volume (WMD =13.75,95％ CI:6.47 ～21.00),splenic vein diameter (WMD =1.34,95％ CI:0.39 ～ 2.30),portal vein diameter (WMD =1.54,95 ％ CI:0.56 ～ 2.52 ;WMD=2.09,95％CI:0.55 ～3.64),portal venous flow (WMD =-5.78,95％ CI:-10.46 ～-1.10;WMD =-5.57,95 ％ CI:-5.92 ～-5.22),difference in portal venous pressure (WMD =1.90,95 ％ CI:1.29～2.50) and ascites (OR =1.83,95％ CI:1.19,2.82).There were no significant differences between patients with and without PVT in terms of sex,age,Child-Pugh classification,prothrombin time,PLT,D-dimer,operating time.Conclusion The risk factors of portal vein thrombosis after splenectomy in cirrhotic patients were splenic volume,splenic vein diameter,portal vein diameter,portal venous flow,difference in portal venous pressure and ascites.

Objective To compare the clinical curative effect between laparoscopic pancreaticoduodenectomy (LPD) and open pancreaticoduodenectomy (OPD) in treatment of terminal bile duct carcinoma.Methods Clincal data of 40 patients with advanced terminal bile duct carcinoma who underwent pancreaticoduodenectomy in our hospital from March 2008 to March 2013 were collected,of which 12 patients were in LPD group and 28 patients in OPD group.Results Hospitalization expense and operative time of patients were in LPD group were both more or longer than those of OPD group (P ＜ 0.05),but haemorrhage,pulling out the drainage tube time,pulling out the stomach tube time,active time post-operation,aeration time,absolute resting on bed time,and hospitalization time in LPD group were lower or shorter than those of OPD group (P ＜ 0.05).There were 15 patients suffered with postoperative complication,including 5 patients in LPD group and 10 patients in OPD group,and there was no significant difference between the two groups in total incidence of postoperative complication (P ＞ 0.05).In the specific postoperative complication,the incidences of biliary fistula of LPD group were higher than those of OPD group (P ＜ 0.05),but incidences of pancreatic fistula,systemic infection,pulmonary infection,incision infection,and delayed gastric emptying between two groups were no significant difference (P ＞ 0.05).All patients were followed up for 1-36 months with the median time of 27 months.During the follow-up periods,in LPD group,8 patients suffered with recurrence,6 patients suffered with tumor metastasis,and 8 patients died;in OPD group,18 patients suffered with recurrence,13 patients suffered with tumor metastasis,and 18 patients died.There were no significant difference between two groups in the recurrence rate,metastasis rate,and mortality (P ＞ 0.05).Conclusion According to the results of the current study,for patients with common bile duct cancer,LPD group was superior to OPD group in the postoperative recovery.But compared with OPD group,it had no obvious advantage in reducing biliary fistula,pancreatic fistula,infection,delayed gastric emptying,and so on,and it also had no obvious advantage in improving the long-term survival situation.However,due to the relatively small sample size of the two groups,the results of this study may lead to some bias,the curative effect of two kinds of surgical comparison still need more clinical research to further explore.

Objective To investigate the prevalence and influencing factors of HIV/AIDS patients with hyperlipidemia before and after receiving antiviral therapy in Wuhan. Methods A retrospective cohort study was used to analyze the data of HIV/AIDS patients in Wuhan from 2004 to 2021. Elevated levels of either TG or TC were determined as hyperlipidemia. Logistic regression model was used to analyze the influencing factors of baseline hyperlipidemia, and Cox proportional risk model was used to analyze the influencing factors of new-onset hyperlipidemia after receiving antiviral therapy. Results A total of 7 562 HIV/AIDS patients were enrolled, 30.61% (2 315/7 562) with hyperlipidemia at baseline and 69.39% (5 247/7 562) without hyperlipidemia. The mean person-years of follow-up for those patients without hyperlipidemia at baseline were 3.48, of whom 33.14% (1 739/5 247) developed hyperlipidemia during follow-up, with an overall density of 9.53/100 person-years. Multivariate logistic regression analysis showed that age ≥30 years and BMI ≥24 kg/m² were positively correlated with baseline hyperlipidemia, while CD4 cell count ≥ 200 μL was negatively correlated with baseline hyperlipidemia. Multivariate Cox model analysis showed that new-onset hyperlipidemia after receiving antiviral therapy was significantly positively correlated with BMI between 18.5-23.9 and ≥24 kg/m², the initial antiviral treatment regimen containing LPV/r, efavirenz and other factors A baseline CD4 cell count of 200 to 349 cells /μL was negatively correlated with new-onset hyperlipidemia. Conclusion HIV/AIDS patients with high BMI and an initial antiviral regimen including Kaletra or efavirenz have a significantly higher risk of hyperlipidemia. Follow-up monitoring of blood lipid in these patients should be strengthened.